^
    HER-2 positive
    Salivary Gland Cancer
    trastuzumab
    Sensitive: A1 - Approval
    Chugai Press Release - 1 week
    No biomarker
    Salivary Gland Cancer
    cisplatin + doxorubicin hydrochloride + cyclophosphamide oral
    Sensitive: A2 - Guideline
    No biomarker
    Salivary Gland Cancer
    cisplatin + vinorelbine tartrate
    Sensitive: A2 - Guideline
    NTRK2 fusion
    Salivary Gland Cancer
    larotrectinib
    Sensitive: A2 - Guideline
    NTRK1 fusion
    Salivary Gland Cancer
    larotrectinib
    Sensitive: A2 - Guideline
    NTRK3 fusion
    Salivary Gland Cancer
    larotrectinib
    Sensitive: A2 - Guideline
    NTRK3 fusion
    Salivary Gland Cancer
    entrectinib
    Sensitive: A2 - Guideline
    NTRK1 fusion
    Salivary Gland Cancer
    entrectinib
    Sensitive: A2 - Guideline
    NTRK2 fusion
    Salivary Gland Cancer
    entrectinib
    Sensitive: A2 - Guideline
    AR positive
    Salivary Gland Cancer
    leuprolide acetate
    Sensitive: A2 - Guideline
    AR positive
    Salivary Gland Cancer
    bicalutamide
    Sensitive: A2 - Guideline
    PD-L1 expression
    Salivary Gland Cancer
    pembrolizumab
    Sensitive: C1 - Off-label
    HER-2 overexpression
    Salivary Gland Cancer
    trastuzumab
    Sensitive: C1 - Off-label
    RET fusion
    Salivary Gland Cancer
    selpercatinib
    Sensitive: C1 - Off-label
    RET fusion
    Salivary Gland Cancer
    pralsetinib
    Sensitive: C1 - Off-label
    HER-2 overexpression
    Salivary Gland Cancer
    trastuzumab
    Sensitive: C2 – Inclusion Criteria
    HER-2 amplification
    Salivary Gland Cancer
    ado-trastuzumab emtansine
    Sensitive: C2 – Inclusion Criteria
    HER-2 amplification
    Salivary Gland Cancer
    trastuzumab
    Sensitive: C2 – Inclusion Criteria
    AR positive
    Salivary Gland Cancer
    leuprolide acetate + bicalutamide
    Sensitive: C3 – Early Trials
    PLIN2 expression
    Salivary Gland Cancer
    leuprolide acetate + bicalutamide
    Sensitive: C3 – Early Trials
    AKT1 E17K
    Salivary Gland Cancer
    AZD5363
    Sensitive: C3 – Early Trials
    HER-2 expression
    Salivary Gland Cancer
    ARX788
    Sensitive: C3 – Early Trials
    HRAS mutation
    Salivary Gland Cancer
    tipifarnib
    Sensitive: C3 – Early Trials
    HER-2 amplification
    Salivary Gland Cancer
    fam-trastuzumab deruxtecan-nxki
    Sensitive: C3 – Early Trials
    HER-2 expression
    Salivary Gland Cancer
    fam-trastuzumab deruxtecan-nxki
    Sensitive: C3 – Early Trials
    PTEN expression
    Salivary Gland Cancer
    bicalutamide
    Sensitive: C3 – Early Trials
    PTEN expression
    Salivary Gland Cancer
    trastuzumab
    Sensitive: C3 – Early Trials
    PTCH1 mutation
    Salivary Gland Cancer
    vismodegib
    Sensitive: C3 – Early Trials
    HER-2 amplification
    Salivary Gland Cancer
    trastuzumab + pertuzumab
    Sensitive: C3 – Early Trials
    HER-2 amplification
    Salivary Gland Cancer
    pyrotinib
    Sensitive: C3 – Early Trials
    HER-2 overexpression
    Salivary Gland Cancer
    trastuzumab + pertuzumab
    Sensitive: C3 – Early Trials
    MET N375S
    Salivary Gland Cancer
    crizotinib + pazopanib
    Sensitive: C3 – Early Trials
    ETV6-NTRK3 fusion
    Salivary Gland Cancer
    larotrectinib
    Sensitive: C3 – Early Trials
    AR positive
    Salivary Gland Cancer
    abiraterone acetate
    Sensitive: C3 – Early Trials
    AR positive + HER-2 amplification
    Salivary Gland Cancer
    leuprolide acetate + bicalutamide
    Sensitive: C4 – Case Studies
    BAG4-FGFR1 B2F6
    Salivary Gland Cancer
    ABSK-091
    Sensitive: C4 – Case Studies
    ETV6-NTRK3 fusion
    Salivary Gland Cancer
    entrectinib
    Resistant: C4 – Case Studies
    PIK3CA H1047R
    Salivary Gland Cancer
    vandetanib
    Sensitive: C4 – Case Studies
    HER-2 amplification + HER-2 mutation
    Salivary Gland Cancer
    trastuzumab
    Sensitive: C4 – Case Studies
    HER-2 positive
    Salivary Gland Cancer
    ACE1702
    Sensitive: C4 – Case Studies